Mesenchymal stem cells (MSCs) are highly useful in a variety of cell therapies owing to their multipotential differentiation capability. MSCs derived from umbilical cord blood are generally isolated by their plastic adherence without using specific cell surface markers and examined for their osteogenic, adipogenic, and chondrogenic differentiation properties retrospectively. Here, we report 2 subpopulations of MSCs, separated based on aldehyde dehydrogenase (ALDH) activity. MSCs with a high ALDH activity (Alde-High) proliferated more than those with a low ALDH activity (Alde-Low). Alde-High MSCs had a greater ability to differentiate than Alde-Low MSCs in in vitro culture. Transplantation of Alde-High MSCs into fractured mouse femurs enabled early repair of tissues and rapid bone substitution. Alde-High MSCs were also more responsive to hypoxia than Alde-Low MSCs, with the upregulation of Flt-1, CXCR4, and Angiopoietin-2. Thus, MSCs with a high ALDH activity might serve as an effective therapeutic tool for healing fractures within a short period of time.
RomanovYA, SvintsitskayaVA, SmirnovVN. 2003. Searching for alternative sources of postnatal human mesenchymal stem cells: candidate MSC-like cells from umbilical cord. Stem Cells, 21:105–110.
5.
CrisanM, YapS, CasteillaL, ChenCW, CorselliM, ParkTS, AndrioloG, SunB, ZhengB, ZhangL, NorotteC, TengPN, TraasJ, SchugarR, DeasyBM, BadylakS, BuhringHJ, GiacobinoJP, LazzariL, HuardJ, PéaultB. 2008. A perivascular origin for mesenchymal stem cells in multiple human organs. Cell Stem Cell, 3:301–313.
DominichiM, BlancKL, MuellerI, Slaper-CortenbachI, MariniFC, KrauseDS, DeansRJ, KeatingA, ProckopDJ, HorwitzEM. 2006. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy, 8:315–317.
14.
RussoJE, HiltonJ. 1988. Characterization of cytosolic aldehyde dehydrogenase from cyclophosphamide resistant L1210 cells. Cancer Res, 48:2963–2968.
15.
RussoJE, HiltonJ, ColvinOM. 1989. The role of aldehyde dehydrogenase isozymes in cellular resistance to the alkylating agent cyclophosphamide. Enzymology and Molecular Biology of Carbonyl Metabolism 2. FlynnTG, WeinerH. Alan R. Liss: New York, 65–79.
16.
StormsRW, TrujilloAP, SpringerJB, ShahL, ColvinOM, LudemanSM, SmithC. 1999. Isolation of primitive human hematopoietic progenitors on the basis of aldehyde dehydrogenase activity. Proc Natl Acad Sci USA, 96:9118–9123.
17.
KastanMB, SchlafferE, RussoJE, ColvinOM, CivinCI, HiltonJ. 1990. Direct demonstration of elevated aldehyde dehydrogenase in human hematopoietic progenitor cells. Blood, 75:1947–1950.
18.
HessDA, MeyerroseTE, WirthlinL, CraftTP, HerrbrichPE, CreerMH, NoltaJA. 2004. Functional characterization of highly purified human hematopoietic repopulating cells isolated according to aldehyde dehydrogenase activity. Blood, 104:1648–1655.
19.
ArmstrongL, StojkovicM, DimmickI, AhmadS, StojkovicP, HoleN, LakoM. 2004. Phenotypic characterization of murine primitive hematopoietic progenitor cells isolation on the basis of aldehyde dehydrogenase activity. Stem Cells, 22:1142–1151.
20.
GinestierC, HurMH, Charafe-JauffretE, MonvilleF, DutcherJ, BrownM, JacquemierJ, ViensP, KleerCG, LiuS, SchottA, HayesD, BirnbaumD, WichaMS, DontuG. 2007. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell, 1:555–567.
21.
NaganoM, YamashitaT, HamadaH, OhnedaK, KimuraK, NakagawaT, ShibuyaM, YoshikawaH, OhnedaO. 2007. Identification of functional endothelial progenitor cells suitable for the treatment of ischemic tissue using human umbilical cord blood. Blood, 110:151–160.
22.
OhnedaO, OhnedaK, AraiF, LeeJ, MiyamotoT, FukushimaY, DowbenkoD, LaskyLA, SudaT. 2001. ALCAM(CD166): its role in hematopoietic and endothelial development. Blood, 98:2134–2142.
23.
LeeOK, KuoTK, ChenWM, LeeKD, HsiehSL, ChenTH. 2004. Isolation of multipotent mesenchymal stem cells from umbilical cord blood. Blood, 103:1669–1675.
24.
CapocciaBJ, RobsonDL, LevacKD, MaxwellDJ, HohmSA, NeelamkavilMJ, BellGI, XenocostasA, LinkDC, Piwnica-WormsD, NoltaJA, HessDA. 2009. Revascularization of ischemic limbs after transplantation of human bone marrow cells with high aldehyde dehydrogenase activity. Blood, 113:5340–5351.
25.
TaguchiK, OgawaR, MigitaM, HanawaH, ItoH, OrimoH. 2005. The role of bone marrow-derived cells in bone fracture repair in a green fluorescent protein chimeric mouse model. Biochem Biophys Res Commun, 331:31–36.
26.
SugiyamaT, KoharaH, NodaM, NagasawaT. 2006. Maintenance of the hematopoietic stem cell pool by CXCL12-CXCR4 chemokine signaling in bone marrow stromal cell niches. Immunity, 25:977–988.
27.
MoritaM, OhnedaO, YamashitaT, TakahashiS, SuzukiN, NakajimaO, KawauchiS, EmaM, ShibaharaS, UdonoT, TomitaK, TamaiM, SogawaK, YamamotoM, Fujii-KuriyamaY. 2003. HLF/HIF-2a is a key factor in retinopathy of prematurity in association with erythropoietin. EMBO J, 22:1134–1146.
28.
MontesinosJJ, Flores-FigueroaE, Castillo-MedinaS, Flores-GuzmánP, Hernández-EstévezE, Fajardo-OrduñaG, OrozcoS, MayaniH. 2009. Human mesenchymal stromal cells from adult and neonatal sources: comparative analysis of their morphology, immunophenotype, differentiation patterns and neural protein expression. Cytotherapy, 11:163–176.
SchugarRC, ChirieleisonSM, WescoeKE, SchmidtBT, AskewY, NanceJJ, EvronJM, PeaultB, DeasyBM. 2009. High harvest yield, high expansion and phenotype stability of CD146 mesenchymal stromal cells from whole primitive human umbilical cord tissue. J Biomed Biotechnol, 2009:1–11.
31.
KöglerG, SenskenS, AireyJA, TrappT, MüschenM, FeldhahnN, LiedtkeS, SorgRV, FischerJ, RosenbaumC, GreschatS, KnipperA, BenderJ, DegistiriciO, GaoJ, CaplanAI, CollettiEJ, Almeida-PoradaG, MüllerHW, ZanjaniE, WernetP. 2004. A new human somatic stem cell from placental cord blood with intrinsic pluripotent differentiation potential. J Exp Med, 200:123–135.
32.
GangEJ, BosnakovskiD, FigueiredoCA, VisserJW, PerlingeiroRC. 2007. SSEA-4 identifies mesenchymal stem cells from bone marrow. Blood, 109:1743–1751.
33.
BühringHJ, BattulaVL, TremlS, ScheweB, KanzL, VogelW. 2007. Novel markers for the prospective isolation of human MSC. Ann NY Acad Sci, 1106:262–271.
34.
BattulaVL, BareissPM, TremlS, ConradS, AlbertI, HojakS, AbeleH, ScheweB, JustL, SkutellaT, BühringHJ. 2007. Human placenta and bone marrow derived MSC cultured in serum-free, b-FGF-containing medium express cell surface frizzled-9 and SSEA-4 and give rise to multilineage differentiation. Differentiation, 75:279–291.
35.
JacksonRL, BakerHN, GilliamEB, GottoAMJr.1977. Primary structure of very low density apolipoprotein C-II of human plasma. Proc Natl Acad Sci USA, 74:1942–1945.
36.
SchölerHR, CiesiolkaT, GrussP. 1991. A nexus between Oct-4 and E1A: implications for gene regulation in embryonic stem cells. Cell, 66:291–304.
37.
MitsuiK, TokuzawaY, ItohH, SegawaK, MurakamiM, TakahashiK, MaruyamaM, MaedaM, YamanakaS. 2003. The homeoprotein Nanog is required for maintenance of pluripotency in mouse epiblast and ES cells. Cell, 113:631–642.
38.
RathjenJ, LakeJA, BettessMD, WashingtonJM, ChapmanG, RathjenPD. 1999. Formation of a primitive ectoderm like cell population, EPL cells, from ES cells in response to biologically derived factors. J Cell Sci, 112:601–612.
39.
LennonDP. EdmisonJM, CaplanAI. 2001. Cultivation of rat marrow-derived mesenchymal stem cells in reduced oxygen tension: effects on in vitro and in vivo osteochondrogenesis. J Cell Physiol, 187:345–355.
40.
RosováI, DaoM, CapocciaB, LinkD, NoltaJA. 2008. Hypoxic preconditioning results in increased motility and improved therapeutic potential of human mesenchymal stem cells. Stem Cells, 26:2173–2182.
41.
Martin-RendonE, HaleSJ, RyanD, BabanD, FordeSP, RoubelakisM, SweeneyD, MoukayedM, HarrisAL, DaviesK, WattSM. 2007. Transcriptional profiling of human cord blood CD133+ and cultured bone marrow mesenchymal stem cells in response to hypoxia. Stem Cells, 25:10003–11012.
42.
RenH, CaoY, ZhaoQ, LiJ, ZhouC, LiaoL, JiaM, ZhaoQ, CaiH, HanZC, YangR, ChenG, ZhaoRC. 2006. Proliferation and differentiation of bone marrow stromal cells under hypoxic conditions. Biochem Biophys Res Commun, 347:12–21.
43.
LiN, LuX, ZhaoX, XiangFL, XenocostasA, KarmazynM, FengQ. 2009. Endothelial nitric oxide synthase promotes bone marrow stromal cell migration to the ischemic myocardium via upregulation of stromal cell-derived factor-1alpha. Stem Cells, 27:961–970.
44.
AraiF, OhnedaO, MiyamotoT, ZhangXQ, SudaT. 2002. Mesenchymal stem cells in perichondrium express activated leukocyte cell adhesion molecule and participate in bone marrow formation. J Exp Med, 195:1549–1563.
GentryT, FosterS, WinsteadL, DeibertE, FiordalisiM, BalberA. 2007. Simultaneous isolation of human BM hematopoietic, endothelial and mesenchymal progenitor cells by flow sorting based on aldehyde dehydrogenase activity: implications for cell therapy. Cytotherapy, 9:259–274.
47.
CaplanAI. 2009. Why are MSCs therapeutic? New data: new insight. J Pathol, 217:318–24.
48.
OkuyamaH, KrishnamacharyB, ZhouYF, NagasawaH, Bosch-MarceM, SemenzaGL. 2006. Expression of vascular endothelial growth factor receptor 1 in bone marrow-derived mesenchymal cells is dependent on hypoxia-inducible factor 1. J Biol Chem, 281:15554–15563.
49.
AbedinM, TintutY, DemerLL. 2004. Mesenchymal stem cells and the artery wall. Circ Res, 95:671–676.
LobovIB, BrooksPC, LangRA. 2002. Angiopoietin-2 displays VEGF-dependent modulation of capillary structure and endothelial cell survival in vivo. Proc Natl Acad Sci USA, 99:11205–11210.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
